
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
0 competitors in Multiple Sclerosis, Relapsing-Remitting
View Full LandscapeTarget Indication
Multiple Sclerosis, Relapsing-Remitting
Clinical Trial
NCT00099502Last updated: 1/27/2026
No patent data available. Pre-approval drugs may not have Orange Book listings.
Betaferon
Betaferon is indicated for the treatment of patients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis; patients with relapsing-remitting multiple sclerosis and two or more relapses within the last two years; patients with secondary progressive multiple sclerosis with active disease, evidenced by relapses.
View on EMAAcute Coronary Syndrome
Overactive Bladder
Pneumonia, Bacterial
Chronic Kidney Disease
Colorectal Neoplasms